What is the purpose of this study?
The purpose of this study is to evaluate whether injectable Buprenorphine compare to injectable placebo reduces methamphetamine use in participants with moderate to severe methamphetamine use disorder with co-occurring mild opioid use disorder or opioid misuse. Twice weekly appointments will be made during the 12 weeks of the medication phase.
You may qualify if you are:
18-65 years of age
Interested in reducing or stopping methamphetamine use
Be willing to comply with all study procedures and medication instructions